233 related articles for article (PubMed ID: 25165100)
1. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Pardee TS; Lee K; Luddy J; Maturo C; Rodriguez R; Isom S; Miller LD; Stadelman KM; Levitan D; Hurd D; Ellis LR; Harrelson R; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2014 Oct; 20(20):5255-64. PubMed ID: 25165100
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Pardee TS; Anderson RG; Pladna KM; Isom S; Ghiraldeli LP; Miller LD; Chou JW; Jin G; Zhang W; Ellis LR; Berenzon D; Howard DS; Hurd DD; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2018 May; 24(9):2060-2073. PubMed ID: 29437791
[No Abstract] [Full Text] [Related]
3. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.
Mohrbacher AM; Yang AS; Groshen S; Kummar S; Gutierrez ME; Kang MH; Tsao-Wei D; Reynolds CP; Newman EM; Maurer BJ
Clin Cancer Res; 2017 Aug; 23(16):4550-4555. PubMed ID: 28420721
[No Abstract] [Full Text] [Related]
6. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Foran J; Ravandi F; Wierda W; Garcia-Manero G; Verstovsek S; Kadia T; Burger J; Yule M; Langford G; Lyons J; Ayrton J; Lock V; Borthakur G; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):223-30. PubMed ID: 24355079
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
[TBL] [Abstract][Full Text] [Related]
8. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Holkova B; Supko JG; Ames MM; Reid JM; Shapiro GI; Perkins EB; Ramakrishnan V; Tombes MB; Honeycutt C; McGovern RM; Kmieciak M; Shrader E; Wellons MD; Sankala H; Doyle A; Wright J; Roberts JD; Grant S
Clin Cancer Res; 2013 Apr; 19(7):1873-83. PubMed ID: 23515411
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
12. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
14. The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner.
Arnold C; Demuth P; Seiwert N; Wittmann S; Boengler K; Rasenberger B; Christmann M; Huber M; Brunner T; Linnebacher M; Fahrer J
Mol Cancer Ther; 2022 Jan; 21(1):100-112. PubMed ID: 34750196
[TBL] [Abstract][Full Text] [Related]
15. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo.
Zachar Z; Marecek J; Maturo C; Gupta S; Stuart SD; Howell K; Schauble A; Lem J; Piramzadian A; Karnik S; Lee K; Rodriguez R; Shorr R; Bingham PM
J Mol Med (Berl); 2011 Nov; 89(11):1137-48. PubMed ID: 21769686
[TBL] [Abstract][Full Text] [Related]
16. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Orlowski RZ; Stinchcombe TE; Mitchell BS; Shea TC; Baldwin AS; Stahl S; Adams J; Esseltine DL; Elliott PJ; Pien CS; Guerciolini R; Anderson JK; Depcik-Smith ND; Bhagat R; Lehman MJ; Novick SC; O'Connor OA; Soignet SL
J Clin Oncol; 2002 Nov; 20(22):4420-7. PubMed ID: 12431963
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Abaza YM; Kadia TM; Jabbour EJ; Konopleva MY; Borthakur G; Ferrajoli A; Estrov Z; Wierda WG; Alfonso A; Chong TH; Chuah C; Koh LP; Goh BC; Chang JE; Durkes DE; Foudray MC; Kantarjian HM; Dong XQ; Garcia-Manero G
Cancer; 2017 Dec; 123(24):4851-4859. PubMed ID: 28841236
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.
von Tresckow B; Sayehli C; Aulitzky WE; Goebeler ME; Schwab M; Braz E; Krauss B; Krauss R; Hermann F; Bartz R; Engert A
Eur J Haematol; 2019 Feb; 102(2):163-173. PubMed ID: 30347469
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of oral topotecan in hematological malignancies.
Beran M; O'Brien S; Thomas DA; Tran HT; Cortes-Franco JE; Giles F; Estey E; Kantarjian HM
Clin Cancer Res; 2003 Sep; 9(11):4084-91. PubMed ID: 14519630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
